CERo Therapeutics Holdings Inc

Cero Therapeutics’ shareholders approved an amendment to the 2024 Equity Incentive Plan that increases the available common stock by 32,000,000 shares, and approved a reverse stock split in ratios from 1:40 to 1:150. They also authorized the issuance of common stock upon conversion of the Series‑E preferred shares, including issuance below the Nasdaq minimum price. Financing measures were expanded: a new share purchase agreement enables up to $14.6 million under an equity‑line program (target $25 million), and the Securities Purchase Agreement was amended and expanded to include an additional purchaser. Clinically, the company reported the third dosing of CER‑1236, completion of the first cohort without dose‑limiting toxicities, and clearance to escalate dosing for cohort 2. » More on de.investing.com

Cero Therapeutics has agreed with an institutional investor on a stock purchase agreement that allows issuance of common stock of up to $14.59 million and continues the existing equity financing program. Daily purchases are possible provided the closing price is at least $0.02, individual transactions are limited and the investor may hold a maximum of 4.99% of outstanding capital; registration rights were also granted. Separately, the company reported progress in the phase‑1 study of CER‑1236 (first cohort completed, no dose‑limiting toxicities, second cohort approved) and adjusted a tranche of the Securities Purchase Agreement (initial closing increased to ~$2.25 million; total financing up to $7 million). » More on de.investing.com